Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07450027) titled 'LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis' on Feb. 27.

Study Type: Observational

Primary Sponsor: Elazig Mental Health and Diseases Hospital

Condition: Methamphetamine Use Disorder Methamphetamine-induced Psychosis

Recruitment Status: Recruiting

Date of First Enrollment: September 1, 2025

Target Sample Size: 120

Countries of Recruitment: Turkey (Turkiye)

To know more, visit https://clinicaltrials.gov/study/NCT07450027

Disclaimer: Curated by HT Syndication....